Upcoming clinical data for novel cardiovascular drug class

Biotech industry reports indicate imminent release of clinical data for a new class of cardiovascular therapeutics. The impact of these findings remains uncertain pending peer-reviewed results, which will determine the potential for market disruption in existing heart disease treatment protocols.